par Delaunoit, Thierry ;Alberts, S R;Sargent, Daniel J;Green, Eva Grace ;Goldberg, Richard;Krook, J;Fuchs, C.;Ramanathan, R K;Williamson, S K;Morton, R F;Findlay, B P
Référence Annals of oncology, 16, 3, page (425-429)
Publication Publié, 2005-03
Référence Annals of oncology, 16, 3, page (425-429)
Publication Publié, 2005-03
Article révisé par les pairs
Résumé : | Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve time to tumor progression (TTP), objective response and overall survival (OS) in patients with metastatic colorectal cancer (MCRC). Here we identify and describe patients treated on Intergroup study N9741 who initially had inoperable MCRC, but who obtained sufficient chemotherapeutic benefit to allow removal of their metastatic disease. |